The aberration of key amino acids participated one-carbon metabolism may jeopardize genetic stability in cancer development Authors: Jue Yang, Rongjun Deng, Xiuyun Bai, Qiqiong Liu, Ying Xing, Yuxing Yao, Wanting Ye, Aiping Lyu, Cheng Lu, Yuanyan Liu Published: 2026 ABSTRACT AbstractOne-carbon (1C) metabolism, primarily orchestrated by key amino acids, serves as a fundamental biochemical hub that sustains diverse physiological functions, especially genetic stability. Given the indispensable role of 1C units in providing building blocks, redox donors, and methyl donors for genomic integrity, deficiencies in 1C-associated amino acids have been proposed to disrupt genome maintenance and potentially promote oncogenic alterations. Such disruptions are suggested to create a permissive environment for oncogenesis, driving epigenetic chaos and gene mutations, which may in turn exacerbate metabolic imbalance. This review comprehensively summarizes the multifaceted roles of 1C metabolism in cellular physiology, with a focus on its function in nucleotide and protein biosynthesis, integrated maintenance of redox equilibrium, and methylation-dependent chromatin remodeling. Special emphasis is placed on elucidating the genetic-level mechanisms through which 1C metabolism influences cancer initiation and progression. Based on systematic analysis of these interconnected pathways, we highlight how dysregulation of 1C metabolism contributes to tumorigenesis, especially through impaired nucleotide synthesis and compromised DNA integrity. Finally, we discuss the emerging therapeutic potential of targeting 1C metabolic pathways in cancer, particularly from the perspective of restoring genomic stability.Keywords: One-carbon metabolism, Genomic instability, Cancer development, Amino acids Introduction One-carbon (1C) metabolism, which encompasses folate cycle, methionine cycle and trans-sulphuration pathway, plays a pivotal role in generation of constructive building blocks, cellular physiology maintenance, cellular energy provision and conduct of crucial signaling molecules for the beginning of life [1]. These pathways are critically dependent on amino acids such as serine, glycine and methionine, which serve as primary donors of 1C units and methyl groups. Mounting evidence establishes that the dysregulation of 1C metabolism is not merely a metabolic consequence of cancer but may also actively contribute to early events in tumor development [2]. However, a key unresolved question remains: how does aberrant 1C metabolism, particularly through its dependence on specific amino acids, influence genomic stability during cancer initiation and progression? Current studies have largely examined 1C metabolism from either a metabolic or epigenetic perspective, often focusing on individual pathways such as the folate or methionine cycles. While these approaches have yielded important insights, fragmented research does not fully explain how metabolic perturbations are translated into genome-wide instability, nor how cancer cells exploit this relationship to sustain evolution and heterogeneity. Of note, the role of amino acids as upstream regulators of 1C flux, as well as their contribution to coordinating nucleotide synthesis, methylation dynamics, and redox homeostasis, remains insufficiently integrated into a unified framework. In fact, growing literature indicates that addressing this gap lies in focusing on key amino acids as central nodes linking 1C metabolism to genomic integrity. Following these clues, we propose a conceptual model in which amino acid availability and utilization shape 1C metabolic flux, thereby influencing three interconnected processes: nucleotide biosynthesis required for DNA replication and repair, methyl donor availability that governs epigenetic landscapes, and redox balance that modulates oxidative DNA damage [3, 4]. Building on this framework, we take pathogenesis as a lens to examine how cancer cells reprogram amino acid-dependent 1C metabolism to support both anabolic growth and genome plasticity, the very destabilization predicted when the coordinated network is disrupted (Fig. 1). Rather than viewing metabolic alterations solely as downstream consequences of oncogenic signaling, this perspective highlights amino acids as a continuous thread throughout 1C metabolism actively determines genetic stability. By integrating metabolic, genomic, and epigenetic dimensions, this review seeks to provide a more cohesive understanding of how metabolic dysregulation contributes to cancer development and to identify potential vulnerabilities for therapeutic intervention. Integrated model of 1C metabolism in driving genomic instability and tumor evolution. Folate cycle, methionine cycle, and trans-sulphuration pathway are metabolically interconnected through 1C unit flow and crosstalk. Their dysregulation leads to dNTP imbalance, aberrant methylation, and redox imbalance, which converge on genomic instability via DNA damage, replication stress, and epigenetic deregulation. By simultaneously perturbing nucleotide pools, methylation patterns, and redox homeostasis, 1C metabolism rewiring creates a multi-hit platform for genomic instability, thereby fueling clonal evolution and tumor progression.Gly, glycine; Ser, serine; Met, methionine; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; Hcy, homocysteine; Cysta, cystathionine; Cys, cysteine; Glu, glutamate; DMG, dimethylglycine; GSH, glutathione; DHFR, dihydrofolate reductase; TYMS, thymidylate synthase; SHMT, serine hydroxymethyltransferase; MTHFR, methylenetetrahydrofolate reductase; MTHFD, methylenetetrahydrofolate dehydrogenase; MS, methionine synthase; MAT, methionine adenyltransferase; BHMT, betaine-homocysteine methyltransferase; DNMTs, DNA methyltransferases; SAHH, S-adenosylhomocysteine hydrolase; CBS, cystathionine β-synthase; CSE, cystathionine γ-lyase; αKB, α-ketobutyrate Key amino acids in one-carbon metabolism drive oncogenic alterations One-carbon (1C) metabolism, which encompasses folate cycle, methionine cycle and trans-sulphuration pathway, relies on a series of key amino acids to provide sufficient substrates and act as redox and electron donors for corresponding metabolic cycle. Collectively, this metabolic system supports the biosynthesis of proteins, nucleotides and lipids, maintains cellular redox homeostasis and supplies methyl donors for epigenetic regulation. Since these 1C-carrying messengers are fundamental to processes that govern genetic integrity, from maintenance to mutation, their metabolic disruption poses a direct threat to genetic stability [5]. It is now widely recognized that tumor progression requires the downregulation of damage surveillance mechanisms and an increase in genetic and epigenetic chaos [6]. Against this backdrop, this review examines the role of perturbed 1C metabolism in both tumor initiation and progression, thus driving the cancer development. Key amino acids mutually provide substrates for genetic material in folate cycle Various kinds of amino acids are involved directly or converted with each other to provide substrates, folates stored moieties, intermediates of metabolic cascades and even redox and methyl donors. As the foundational metabolic inputs, these amino acids serve as active 1C messengers in biosynthetic process of proteins and nucleotides for genetic maintenance, modification or even mutation [5]. Due to the extensive and intricate participation of amino acids in 1C metabolism, we cannot summarize all involved amino acids here but instead focus on some key inter-convertible examples such as serine, glycine, dimethylglycine, sarcosine, threonine, homocysteine and methionine, which collectively support folate-mediated 1C flux. Serine-glycine axis as the primary source of 1C units The initiation of 1C flux primarily relies on amino acids, with serine serving as the dominant donor. Through serine hydroxymethyltransferase (SHMT), serine is converted to glycine while transferring a 1C unit to tetrahydrofolate (THF), generating 5,10-methylene-THF (5,10-me-THF) [7]. This intermediate occupies a central metabolic branch point: it can be oxidized to 10-formyl-THF for purine synthesis or irreversibly reduced to 5-mTHF by MTHFR, which subsequently supports methionine regeneration from homocysteine (Hcy) [8, 9]. The serine-glycine interconversion is reversible and represents the chemical engine of the cycle [5]. In mitochondria, glycine can be further metabolized by the glycine cleavage system (GCS) to provide 1C units in the form of 5,10-me-THF, releasing the second carbon atom of glycine as CO2. Furthermore, glycine contributes directly to the purine ring structure, linking 1C metabolism to both nucleotide biosynthesis and redox homeostasis [10]. Beyond serine and glycine, additional amino acids act as auxiliary fuels; dimethylglycine and sarcosine undergo stepwise demethylation to generate glycine, thereby feeding into the folate cycle. In certain mammalian cells, threonine can also be converted to glycine via threonine dehydrogenase (TDH), providing an alternative route for 1C unit generation [11] (Fig. 2). Compartmentalized one-carbon metabolism network. Serine driven 1C metabolism is compartmentalized into mitochondria, cytosol, and nucleus, where folate polyglutamation ensures intracellular retention and compartment-specific metabolic flux. Under proliferative conditions or genotoxic stress, 1C enzymes (e.g. SHMT1/2, MTHFD) translocate to the nucleus. Here, nuclear 1C metabolism supports local dTMP-synthesis and dynamically modulates DNA and histone methylation, linking 1C flux to epigenetic regulation of gene expression. GCP II, glutamate carboxypeptidase II; FR, folate receptor; RFC, reduced folate carrier; MFT, Mitochondrial folate transporter; AAT: amino acid transporter; AAs, amino acids; Ser, serine; Gly, glycine; other abbreviations are covered in the article In summary, diverse amino acids sustain the folate cycle by providing 1C units that support nucleotide biosynthesis and genomic stability. Among them, serine acts as a central metabolic hub, linking nucleotides synthesis, methylation reactions and redox balance Polyglutamation and compartmentalization jointly ensure folate metabolic stability The stability of folate cycle relies on the synergistic actions of polyglutamation and intracellular compartmentalization, which together ensure cellular folate retention, precise distribution, and efficient utilization of 1C units. Mammals cannot synthesize folate de novo and therefore depend on dietary intake [12]. Most dietary folates exist in a polyglutamyl form, which is cleaved to monoglutamates for absorption. Intracellular retention through polyglutamation Upon entering cells, folates are reconverted into polyglutamates by folylpolyglutamate synthase (FPGS). This polyglutamation serves two critical purposes: first, it traps folates within the cell by reducing their affinity for export transporters, establishing a stable folate reservoir; second, it enhances the binding affinity of folates to various enzymes, making them superior metabolic substrates [13]. Folate-mediated 1C metabolism operates in separate mitochondrial and cytosolic compartments, each housing distinct but analogous sets of enzymes dedicated to specific functions, such as purine synthesis in the cytosol and thymidylate synthesis in both compartments. This compartmentalization allows for independent regulation within specialized biochemical environments. Its stability is maintained by several intertwined mechanisms: first, the distribution of isozymes (e.g., SHMT1 and SHMT2) between compartments ensures the proper channeling of metabolites [14]; second, FPGS itself exists as compartment-specific isoforms targeted to the cytosol and mitochondria [15]. The directionality of this network typically flows from mitochondria to the cytoplasm. Importantly, emerging evidence has expanded this model by demonstrating that 1C metabolic enzymes can dynamically relocalize to the nucleus. Under conditions of high proliferative demand, key enzymes such as SHMT1/2 translocate to the nucleus to locally generate 1C units [5, 16]. This spatial redistribution ensures that metabolic flux is directly coupled to local genomic needs. However, cancer cells exploit this architecture, channeling a continuous supply of mitochondrial formate to drive rampant nucleotide synthesis in the cytosol. In summary, the coordinated action of FPGS-mediated polyglutamation and the enzyme-defined architecture of metabolic compartmentalization allows the cell to establish a highly stable and efficient 1C metabolic network. Polyglutamation enables intracellular folate retention and functional activation, while compartmentalization ensures pathway segregation and directed flux. Importantly, this compartmentalization should be viewed as a dynamic and multi-layered system encompassing mitochondrial, cytosolic, and nuclear domains, rather than a static spatial separation. Together, these mechanisms form the cornerstone for maintaining genetic stability and metabolic homeostasis. However, cancer cells adeptly exploit and corrupt this very architecture to fuel their progression. The mitochondrial-to-cytosolic 1C flux, although segregated, becomes hyperactive, channeling a continuous supply of formate to drive rampant nucleotide synthesis for unchecked DNA replication. This metabolic reprogramming creates a profound dependency, such that even when the predominant mitochondrial serine pathway is inhibited, tumors can evade death by upregulating compensatory cytosolic 1C flux to sustain growth [17]. Concurrently, aberrant activation of nuclear 1C metabolism may further reinforce oncogenic programs by reshaping local epigenetic landscapes, thereby promoting transcriptional plasticity and adaptation. Thus, the dysregulation of this precise system, from folate activation to compartmentalized flux is suggested to not merely accompany but actively contributes to tumorigenesis, making the entire 1C metabolic network a compelling therapeutic target. Methionine cycle may generate reactive 1C units The methionine cycle is intricately interconnected with the folate cycle through 1C metabolism, collectively forming a critical biochemical network responsible for generating the key cellular active methyl donor in the form of S-adenosylmethionine (SAM). This integrated system facilitates the transfer of methyl units for numerous epigenetic modifications and biochemical processes, including the methylation of proteins, nucleic acids (DNA/RNA) and membrane phospholipids, thereby regulating essential biological functions [18]. As an essential amino acid, methionine serves dual roles as both the initiator and key substrate of the cycle and it is primarily obtained through dietary sources or via Hcy remethylation, the crucial metabolic intersection linking folate and methionine cycles. The metabolic flux through this pathway initiates with the transfer of a methyl group from 5-mTHF to Hcy, catalyzed by methionine synthase (MS) with the 1C unit derived from the folate cycle. This reaction simultaneously regenerates THF to sustain the folate cycle, produces methionine [19] (Fig. 3a). Subsequently, under the action of methionine adenyltransferase (MAT), methionine couples with adenosine triphosphate (ATP) in an adenylation reaction to form SAM, which is acknowledged as the primary active methyl donor reagent for crucial methylation reactions that take place in all living organisms [20] (Fig. 3b). For instance, SAM provides three successive methyl groups to phosphatidylethanolamine (PE) to generate phosphatidylcholine (PC), which is a critical process maintaining membrane integrity and cellular homeostasis [21]. Connecting the folate and methionine cycles for SAM and ATP biosynthesis. This schematic illustrates the synergistic carbon flux supporting SAM and ATP biosynthesis. a Folate cycle and Met formation: One-carbon units from various donors (Ser, Thr, Sar, DMG) fuel the cycle to produce 5-mTHF, which remethylates Hcy to Met. b ATP biosynthesis: 10-formylTHF and CO2 provide essential carbon atoms for adenine ring construction and subsequent ATP generation. c SAM generation: Met and ATP converge to synthesize SAM. Molecular structures highlight the chemical groups (adenosyl and methionine) derived from each precursor Following methyl group donation, SAM converts to S-adenosylhomocysteine (SAH), a potent product inhibitor of most methyltransferases. SAH is subsequently hydrolyzed by SAH hydrolase (SAHH) to yield adenosine and Hcy. At this metabolic crossroads, Hcy partitioning is strictly regulated to maintain the cellular methylation potential as defined by the SAM/SAH ratio [22]. Hcy primarily undergoes remethylation via two distinct routes: the ubiquitous, folate-dependent pathway catalyzed by methionine synthase (MS), and the folate-independent pathway catalyzed by betaine-homocysteine methyltransferase (BHMT). Crucially, while the MS pathway operates in nearly all tissues, its activity is exquisitely sensitive to nutritional folate status and systemic one-carbon unit availability. In contrast, BHMT expression is largely restricted to hepatic and renal tissues, where it utilizes pre-formed methyl groups from betaine. This tissue-specific distribution establishes BHMT as a critical metabolic buffer; in healthy liver tissue, the synergy between BHMT and MS maintains a stable supply of methionine and SAM, effectively shielding the genome from the mutagenic effects of Hcy accumulation and folate fluctuations, a protective capacity notably absent in peripheral tissues such as the colon or brain. The aberration of this metabolic balance is a hallmark of cancer development. In many malignancies, particularly hepatocellular carcinoma, the silencing or downregulation of BHMT represents a pivotal metabolic shift. This loss of BHMT-mediated buffering unmasks the underlying dependence of hepatocytes on the folate-dependent MS pathway, which is often insufficient to maintain the high SAM demand of transformed cells. This leads to a localized methionine crisis and an elevation of the SAH/SAM ratio, which triggers global DNA hypomethylation. Such epigenetic aberrations are proposed to jeopardize genetic stability by promoting chromosomal instability, reactivating transposable elements, and silencing tumor suppressor genes through stochastic methylation errors. Conversely, in peripheral tumors lacking BHMT, the MS pathway is frequently hijacked to prioritize amino acid flux toward nucleotide synthesis at the expense of methylation fidelity, thereby eroding the precise epigenetic landscape required for genomic stability [23]. Thus, the interplay between folate- and betaine-dependent remethylation represents more than a redundant loop; it is a fundamental regulatory axis that differentially governs the susceptibility of hepatic versus extrahepatic tissues to methylation stress. Any aberration in this system, whether through nutritional deficiency or enzymatic dysregulation, undermines global methylation capacity, creating a permissive environment for the genomic instability that fuels cancer progression. Trans-sulphuration pathway generates redox intermediates Trans-sulphuration pathway serves as a crucial metabolic hub that orchestrates sulfur-containing amino acid metabolism, playing a pivotal role in maintaining cellular sulfur homeostasis and redox balance. Through the regulation of the methionine-cysteine conversion process, in which the transfer of sulfur from Hcy to cysteine represents the sole pathway for de novo cysteine biosynthesis in mammals, this regulatory mechanism not only sustains sulfur homeostasis but also furnishes precursors for crucial antioxidant molecules like GSH [24]. The pathway involves the following key reactions: Hcy condenses with serine to generate cystathionine via the enzyme cystathionine β-synthase (CBS). This intermediate is subsequently cleaved by cystathionine γ-lyase (CSE), yielding α-ketobutyrate (αKB) and cysteine [25]. The generated cysteine then enters distinct metabolic branches: serving as a precursor for protein synthesis; participating in GSH biosynthesis through sequential conjugation with glutamate and glycine, catalyzed by γ-glutamyl cysteine synthetase (γ-GCS) and glutathione synthetase (GS); or being converted to other biologically significant sulfur-containing molecules, including hydrogen sulfide (H2S) and taurine [26]. This metabolic versatility underscores the central role of cysteine in cellular homeostasis, functioning not only as a proteinogenic amino acid but also as a critical component in antioxidant defense systems and cellular signaling pathways. Consequently, dysregulation of sulfur-containing amino acid metabolism has been linked to perturbations in cellular redox homeostasis and is proposed to impair DNA repair fidelity. Specifically, insufficient cysteine availability restricts GSH synthesis, compromising antioxidant capacity and leading to reactive oxygen species (ROS) accumulation and oxidative DNA damage. Moreover, the activity of key DNA repair enzymes is modulated by cellular redox status, and their dysfunction further exacerbates genomic instability. Ultimately, these processes are thought to contribute to oncogenic transformation through the accumulation of oxidative DNA lesions and genetic mutations. Beyond the direct consequences of oxidative stress, a critical yet often underappreciated impact of enhanced trans-sulphuration flux is its competitive pressure on methyl group availability. Homocysteine occupies a central metabolic node where it can either be remethylated to regenerate methionine and sustain SAM-dependent methylation reactions or be irreversibly diverted into the trans-sulphuration pathway for cysteine and GSH synthesis. Under conditions of metabolic stress or nutrient limitation such as folate or vitamin B deficiency, serine/glycine restriction, or increased oxidative burden in which cells preferentially channel homocysteine toward trans-sulphuration to reinforce antioxidant defenses. While this metabolic adaptation supports redox homeostasis, it may come at the expense of methyl donor availability. Reduced remethylation flux limits methionine regeneration and consequently decreases intracellular SAM levels, thereby lowering the SAM/SAH ratio, a key determinant of cellular methylation potential. This shift can impair DNA and histone methylation, leading to epigenetic dysregulation, altered chromatin accessibility, and aberrant gene expression. In the stressed tumor microenvironment, this prioritization of trans-sulphuration creates a metabolic trade-off: cells survive by enhancing their antioxidant capacity but simultaneously exacerbate epigenetic instability, further fueling cancer development. From an evolutionary perspective, the directionality of this pathway exhibits significant variation across species. While prokaryotes, fungi and plants possess the metabolic flexibility to reversibly convert cysteine to methionine, mammals have evolved an irreversible trans-sulphuration pathway [27]. This evolutionary adaptation reflects the specialized metabolic requirements of mammalian systems, where the unidirectional nature of the pathway ensures efficient sulfur redistribution and antioxidant production. To avoid confusion, the trans-sulphuration pathway in the context of this review referred to an irreversible process in mammals, distinguishing it from the bidirectional pathways observed in other organisms. The role of intracellular amino acid homeostasis in regulating 1C metabolism Given that multiple amino acids serve as primary donors and regulators within 1C metabolism, the maintenance of intracellular amino acid homeostasis plays an essential role in sustaining 1C metabolic flux. Since amino acids exceeding the immediate demands of protein synthesis are generally redirected toward catabolic or biosynthetic pathways, their intracellular availability must be tightly coordinated through sensing and feedback mechanisms. These regulatory systems ensure a balanced amino acid pool that can dynamically support nucleotide biosynthesis, methylation reactions, and the maintenance of genomic integrity. Amino acid availability and sensing mechanisms Under physiological conditions, intracellular amino acid levels, including their uptake, synthesis, and utilization, are tightly regulated by integrated nutrient-sensing pathways. Two major systems, general control nonderepressible 2 (GCN2) and mechanistic target of rapamycin complex 1 (mTORC1), play complementary roles in maintaining this balance [28]. GCN2 functions as a sensor of amino acid deprivation by detecting the accumulation of uncharged transfer RNAs (tRNAs). Upon activation, GCN2 phosphorylates eukaryotic initiation factor 2α (eIF2α), leading to a global attenuation of protein translation and a consequent reduction in amino acid consumption [29]. At the same time, this signaling selectively enhances the translation of activating transcription factor 4 (ATF4), which transcriptionally upregulates genes involved in amino acid transport and biosynthesis, including members of the solute carrier (SLC) family. This adaptive response increases amino acid uptake and promotes the synthesis of key metabolites, particularly serine and glycine. However, the role of the GCN2-eIF2α-ATF4 axis is not universally cytoprotective; its impact appears context-dependent. While acute activation supports 1C metabolic flux, chronic or excessive GCN2 signaling can paradoxically trigger apoptosis through the induction of CHOP, suggesting a fine-tuned threshold between metabolic adaptation and cell death that is often overlooked in descriptive models [30]. Furthermore, most mechanistic insights into these sensing pathways have been derived from in vitro studies using nutrient-defined media, which may not accurately reflect the complex, fluctuating amino acid gradients present in physiological tissues [31]. In contrast, mTORC1 serves as a central sensor of amino acid sufficiency, coordinating anabolic growth programs. When amino acids are abundant, mTORC1 is activated through Rag GTPase-dependent recruitment to the lysosomal surface, a process regulated by upstream amino acid sensors acting via the GATOR1-GATOR2 complex. Activated mTORC1 promotes protein synthesis and cell growth by phosphorylating downstream targets such as ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1) [28]. In parallel, mTORC1 enhances metabolic pathways that support biosynthesis, thereby linking amino acid availability to cellular proliferation. Notably, recent evidence highlights a complex crosstalk where mTORC1 can suppress GCN2 activity, yet both pathways may be simultaneously active in different sub-regions of the same tissue, a spatial heterogeneity that challenges the traditional binary switch model of nutrient sensing. Rewiring of amino acid sensing in cancer In the context of malignancy, the balance between amino acid availability and metabolic demand is frequently disrupted. Oncogenic signaling often results in sustained activation of mTORC1, partially uncoupling anabolic processes from nutrient availability. Mechanistically, mTORC1 promotes the mitochondrial tetrahydrofolate (mTHF) cycle through ATF4-dependent upregulation of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), thereby enhancing mitochondrial one-carbon flux. These 1C units are preferentially directed toward purine nucleotide biosynthesis, supporting the increased anabolic requirements of rapidly proliferating cancer cells [32]. As a result, activation of the mTHF pathway contributes to maintaining elevated 1C flux and facilitates tumor growth. Meanwhile, tumor cells frequently exploit the GCN2-ATF4 axis as an adaptive mechanism to cope with nutrient stress within the tumor microenvironment. This pathway is often upregulated under conditions of limited nutrient supply, promoting de novo amino acid synthesis and enhancing amino acid transport. Such metabolic reprogramming helps sustain one-carbon metabolism and alleviates replication stress, thereby supporting tumor cell survival under adverse conditions. Importantly, not all tumor types exhibit uniform dependence on these pathways. Emerging evidence indicates that certain cancers display limited reliance on GCN2 signaling or can bypass amino acid stress responses through alternative metabolic routes, such as increased nutrient scavenging or stromal support [33]. In addition, the majority of current evidence linking GCN2/mTORC1 signaling to 1C metabolism is based on cell culture or animal models, whereas clinical data remain relatively sparse and sometimes inconsistent [34]. These limitations underscore the need for integrative studies that combine metabolic flux analysis, genetic models, and patient-derived data to clarify the physiological and pathological relevance of these pathways. Methionine sensing and SAM-dependent regulation of 1C metabolism Among amino acids, methionine plays a particularly important role in linking amino acid availability to one-carbon metabolism through its conversion to SAM, the universal methyl donor. Cellular SAM levels are sensed by SAMTOR, a key regulator of mTORC1 signaling [35]. Under conditions of sufficient methionine, SAM directly binds to SAMTOR, disrupting the SAMTOR-GATOR1 interaction and leading to activation of mTORC1 [36]. Through this mechanism, methionine availability is tightly coupled to anabolic signaling and methylation capacity. This methionine-SAM-mTORC1 axis not only regulates protein synthesis but also modulates SAM-dependent methylation reactions, including DNA and histone methylation. Dysregulation of this sensing pathway is commonly associated with methionine dependence in cancer cells, which exhibit an increased requirement for SAM to sustain aberrant epigenetic modifications. Consequently, enhanced methionine metabolism supports both nucleotide synthesis and epigenetic reprogramming, contributing to tumor progression and genomic instability. 1C metabolism provides the constructive building blocks for gene mediated cell proliferation Turnover of specific amino acid components into 1C metabolism that are processed through the three reactive cycles, may output diverse constructive building blocks with informative biological functions. Here, we emphatically outline some building blocks conducted at gene levels for tumor cell proliferation, such as basic groups to assemble nucleotides, biosynthetic amino acid to trigger metabolic rewiring and biomacromolecules to maintain genomic integrity [37]. Importantly, dysregulation of these components contributes not only to proliferative capacity but also to tumor initiation. Specifically, perturbations in 1C metabolism disrupt nucleotide biosynthesis, leading to imbalanced nucleotide pools, replication stress, and increased rates of DNA misincorporation and DSBs, hallmarks of genomic instability. Such instability provides a substrate for oncogenic transformation. In many cancers, these pathways are aberrantly upregulated through multiple mechanisms, including direct transcriptional activation by oncogenic mutations, indirect modulation via altered translation of upstream or downstream regulators, and signaling pathway–driven expression of bioactive mediators. Collectively, these alterations reinforce both metabolic adaptation and the accumulation of genetic lesions that underpin tumor initiation. Folate cycle provides nucleotide blocks and 1C units for genome maintenance Building upon the amino acid-derived substrates and the compartmentalized enzymatic framework described above, the folate cycle fulfills its ultimate biological function: safeguarding genomic integrity. By delivering activated one-carbon units in distinct oxidative states, this cycle orchestrates the precise assembly of the genetic building blocks essential for DNA and RNA synthesis [15]. Downstream impact on purine and thymidylate pools The metabolic outputs of the folate pool, specifically 10-formyl-THF and 5,10-me-THF, are indispensable for maintaining the structural integrity of the genome. Purine nucleotide bases, which are divided into adenine (A) and guanine (G), are generated from the folate pool through the intermediate 10-formyl-THF, which donates 1C units to carbon atoms 2 and 8 of the purine backbone [38]. The 1C units of 10-formyl-THF are originally from serine and glycine and glycine is required for purine synthesis because it can donate nitrogen atom 7 and carbon atoms 4 and 5 for purine ring [39]. Simultaneously, the folate cycle sustains the production of ATP, which acts as both an energy carrier and a substrate for SAM generation [40, 41] (Fig. 3c). The cycle also modulates the synthetic processes of thymidylate. 5,10-me-THF is required for conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP, thymidylate) which is one of the building blocks of DNA. And the de novo thymidylate synthesis is a pathway which involves the folate-dependent enzymes SHMT, thymidylate synthase (TYMS) and dihydrofolate reductase (DHFR) [42]. The efficiency of these reactions directly determines the fidelity of DNA replication and gene expression [43]. Consequences of metabolic dysfunction for genomic stability Genome maintenance requires the precise balance of these nucleotide precursors, a process often jeopardized in cancers [44]. When folate-mediated 1C-flux is disrupted, an imbalance between dUMP and thymidylate occurs. As a result, uracil is incorporated into DNA by mistake, contributing to double-strand breaks (DSBs), chromosomal abnormalities, and genetic instability [45]. Furthermore, in scenarios of metabolic stress, such as SHMT depletion, the cell may prioritize the methionine cycle at the expense of thymidylate synthesis. The resulting dysfunction of these genetic blocks is suggested to act as a potent driver of gene defects and oncogenic mutations, underscoring the importance of properly regulated 1C metabolism in preventing the genetic alterations that drive cancer. 1C metabolism supplies amino acid building blocks to fuel metabolic rewiring in cancer To meet the insatiable proliferation demand of cancer cells, metabolic rewiring becomes significant and even indispensable for sustaining aggressive phenotypes, particularly under nutrient-limited conditions. 1C metabolism serves as a critical junction that fuels this rewiring by supplying essential amino acid building blocks. These amino acids are efficiently utilized in the translation and generation of biomacromolecules and proteins, some of which may act as key substrates and catalysts for metabolic rewiring. In addition, amino acids may act as fuels to trigger metabolic aberration and propagate signals to coordinate biomass production of gene expression and nutrient utilization to support oncogenic growth. 1C metabolism driven amino acid supply promotes protein synthesis in proliferating cancer cells Protein translation is the process in which the genetic information encoded in messenger RNA (mRNA) is utilized to synthesize proteins. In this process, transfer RNA (tRNA) functions as a key tool for amino acid transport. Under the catalysis of aminoacyl tRNA synthetase, tRNA transports specific amino acids to the ribosome. It accurately recognizes the codon sequence on mRNA through its anticodon, then specifically incorporates specific amino acids into the peptide chain [46]. 1C metabolism generates some specific amino acids blocks such as methionine and hypusine, which can promote mRNA translation from different aspects to support protein synthesis involved in metabolic rewiring. It is worth mentioning that as the amino acid encoded by the start codon, methionine is the initiator of protein translation. As mentioned earlier, methionine can only be obtained exogenously or generated by the regeneration of methionine from Hcy in 1C metabolism. Therefore, 1C metabolism, as a fundamental pathway of methionine biosynthesis, is essential for the generation of proteins. Furthermore, heightened concentrations of SAM may act as a signal that stimulates cells to undergo growth and division. In this process, cells utilize SAM in a process involving methylthioadenosine (MTA) to generate polyamines, which in turn leads to a reduction in SAM levels [47]. Among these polyamines, spermidine promotes the generation of hypusine, a compound that is crucial for eukaryotic translation. This is because hypusine is necessary for the association of eukaryotic initiation factor 5 A (eIF5A) with ribosomes [48] (Fig. 4). The mechanisms of biomacromolecules derived from 1C metabolism on genomic integrity. In 1C metabolism, amino acids serve as key precursors for biosynthesis of biomacromolecules as nucleic acids and proteins. Folate cycle, a central component of 1C metabolism, provides the necessary building blocks and 1C units for the synthesis of purines and dTMP, which play crucial roles in gene expression and genome maintenance. Additionally, 1C metabolism supports protein synthesis through (1) methionine as the universal translation initiator; (2) SAM-derived polyamines that activate eIF5A. These mechanisms collectively promote the synthesis of biological macromolecules, including proteins and nucleic acids, which are essential for maintaining genetic stability and enabling a wide range of physiological functions Amino acid-driven rewiring of 1C metabolism and its impact on cellular proliferation In response to changes in nutrient availability or cellular stress, cells can rewire their metabolism. As mentioned above, 1C metabolism can drive this rewiring through protein translation [4]. During fasting or a low-protein diet, cells may increase the breakdown of endogenous proteins to release amino acids. These amino acids can then be funneled into 1C metabolism pathways for biomass production. The resulting changes in 1C metabolism can affect protein translation by influencing the availability of nucleotides for ribosome synthesis and mRNA stability [37]. In cancer cells, there is often a rewiring of metabolism to meet the rapid proliferation purpose of 1C units supply and nutrient utilization. The demand for amino acids is high to support rapid protein synthesis and cell proliferation [49]. Simultaneously, 1C metabolism is upregulated in cancer cells to fulfill the prerequisites for nucleotide synthesis and other biosynthetic pathways. Amino acids are redirected into 1C metabolism, thereby supplying the requisite substrates for the generation of thymidylate and other nucleotides [50]. Consequently, this process drives protein translation and promotes cell growth, thereby underscoring the intricate interconnections among amino acid metabolism, 1C metabolism and protein translation within the framework of metabolic rewiring. In conclusion, amino acids-participated 1C metabolism is essential for cell growth and providing precursors for the biosynthesis of nucleic acids and proteins, which are critical for maintaining genetic stability and enabling physiological functions. Stable genetic inheritance depends on the adequate supply of nucleotide precursors for DNA replication and repair, while stable gene expression relies on the synthesis of proteins and signaling molecules. Of note, the aberrant 1C metabolism or 1C metabolism hijacked by oncogenes, may breakdown gene stability, through interfering nucleotide precursors biosynthesis involved in genome maintenance and its conducted proteins expression for signaling transduction and vice versa. Meanwhile, metabolic rewiring as a prerequisite for genetic alteration and tumor expansion, which require adequate amino acids supplied from 1C metabolism to assemble corresponding biomacromolecules and proteins as structural support, may initiate and trigger multiple metabolic pathways, providing sufficient fuels and metabolites to ensure proliferation. Among them, nucleotides synthesized through folate cycle aid to generate DNA are indispensable for DNA replication, ensuring genome integrity and safeguarding genetic stability. Dysregulation of this process may compromise DNA repair and replication fidelity, providing basic construction blocks for oncogenic mutations. In addition, precursors generated from methionine cycle, specifically methionine and its derivative SAM, are indispensable for protein translation. SAM fuels polyamine biosynthesis, which in turn enables the hypusine modification of eIF5A, which is a critical regulator of ribosome function and mRNA translation fidelity Table 1. Table 1Summary of the core biological roles of 1C metabolismFunctionKey metabolites/EnzymesBiological significanceReferenceNucleotide synthesisdUMP, dTMP, Purines, DHFR, TYMSProvides essential precursors for DNA replication and RNA transcription; critical for maintaining genomic integrity. [18, 42]Methyl donor generationSAM, Methionine, MAT, SAHProduces SAM, the universal methyl donor for DNA, histones, proteins, and lipids. [22, 40, 47]Redox homeostasisCysteine, GSH, NADPH, MTHFRRegulates the trans-sulphuration pathway to produce GSH, neutralizing ROS and maintaining cellular redox balance. [51–53]Amino acid homeostasisSerine, Glycine, MethionineActs as a metabolic hub for amino acid interconversion,supporting protein synthesis and cell growth signaling (e.g., mTORC1). [35, 54, 55] Summary of the core biological roles of 1C metabolism Acts as a metabolic hub for amino acid interconversion, supporting protein synthesis and cell growth signaling (e.g., mTORC1). The role of 1C metabolic intermediates in maintaining genomic integrity by regulating cellular redox balance Hypoxia is a significant character for tumor invasion and angiogenesis, which accumulates more ROS due to the electrons leaking out from mitochondrial electron transport chain (ETC) with low oxygen levels. Trans-sulphuration pathway generated redox intermediates that widely modulate the cellular redox processes through cellular and genetic signaling transduction, mitochondria mediated energy production, immune responses and cellular stress adaption, which play a pivotal role in regulating cell survival and death. Redox imbalance is associated with disrupts to the integrity of biological macromolecules, and is thought to interfere with genetic expression, the overloaded actions of which potentially trigger mutations and contribute to tumor progression in severe cases. In addition, although immune cells activation dependent on proper ROS levels, immunosuppressive cell populations are more resistant to hypoxia and oxidative TME, leading to immune escape. Notably, intermediates as NADPH and GSH derived from 1C metabolism play indispensable roles in ROS scavenging and redox homeostasis, which are fundamental for maintaining a balance between ROS generation and elimination. Proper redox regulation can mitigate the adverse effects of oxidative stress on cellular structures and immune response, thereby inhibiting damage, enhancing anti-tumor immunity and potentially improving therapeutic outcomes. Importantly, ROS-mediated effects are highly dose- and context-dependent rather than uniformly deleterious. Physiological ROS levels (typically in the low nanomolar range for species such as H2O2) function as signaling molecules regulating proliferation, differentiation, and immune activation. However, when ROS levels exceed the buffering capacity of antioxidant systems, often due to mitochondrial dysfunction, hypoxia-induced ETC leakage, or oncogene-driven metabolic reprogramming, cells enter a state of oxidative stress. Although precise quantitative thresholds vary across cell types and subcellular compartments, a critical determinant of ROS toxicity is the balance between production rates and detoxification capacity (e.g., NADPH/GSH availability), rather than absolute ROS concentration alone. This dynamic threshold model better explains why cancer cells can tolerate chronically elevated ROS yet remain vulnerable to further oxidative insults. The main redox intermediates produced in 1C metabolism NADPH and GSH are two main redox intermediates produced in 1C metabolism, playing crucial roles in antioxidant defense to maintain the redox balance [56]. While 1C metabolism produces numerous intermediates involved in redox homeostasis, space limitations preclude a full discussion of all contributors. Thus, this review focuses specifically on these two critical redox regulators due to their central importance in cellular health. Under tumor pathological circumstances, to neutralize the excessively generated ROS during rapid proliferation in hypoxia microenvironment, overloaded NADPH and GSH are demanded through 1C metabolism to regenerate the reduced pools, the inability of which leads to an oxidative tumor microenvironment (TME) (Fig. 5). 1C metabolism-redox coupling in tumor progression and immunity. This schematic illustrates how 1C metabolism governs redox homeostasis to coordinate genomic integrity and anti-tumor immune surveillance. In the initial stage, serine- and folate-driven 1C metabolism sustains SAM and GSH synthesis, constraining ROS within physiological thresholds and preserving genome stability. Disruption of this metabolic axis elevates ROS levels, precipitating DNA damage and genomic instability that drive malignant initiation. Redox balance further dictates immune outcome: an equilibrated environment supports CD8⁺ T cell cytotoxicity, whereas oxidative stress fosters an immunosuppressive milieu characterized by Treg expansion, MDSC accumulation, and immune checkpoint engagement, thereby facilitating tumor immune escape. Collectively, the functional coupling of 1C metabolism and redox regulation constitutes a central nexus linking metabolic reprogramming, genomic maintenance, and immune control in cancer progression Folate cycle-derived NADPH sustains redox balance and metabolism NADPH is well known as an essential electron donor and an indispensable cofactor for reductive biosynthesis and redox homeostasis. It transfers and stores reduction potential for numerous anabolic reactions such as protein synthesis and glycogen synthesis [57]. Notably, 1C metabolic transformations interface with redox regulation through folate cycle-mediated NADPH generation. While most reactions in the folate cycle are reversible, the exception lies in the irreversible oxidation of 10-formyl-THF to CO2, a reaction generates an equivalent amount of NADPH. This mitochondrial-localized process assumes particular significance in maintaining redox homeostasis within energy-generating organelles. As the major site of oxidative phosphorylation and ROS generation, mitochondria rely on NADPH to support antioxidant defenses and ensure efficient operation of energy metabolism. The NADPH generated through this pathway sustains a reduced microenvironment within mitochondria, facilitates antioxidant defense mechanisms and ensures proper functioning of enzymes involved in energy transduction. 1C metabolism sustains GSH-dependent antioxidant defense GSH, synthesized through the trans-sulphuration pathway from precursor amino acids, constitutes the primary non-enzymatic antioxidant maintaining intracellular redox balance. The redox-active thiol moiety of GSH undergoes oxidation to glutathione disulfide (GSSG) during radical scavenging processes. Specifically, glutathione peroxidase (GPx) catalyzes the reduction of hydrogen peroxide (H2O2) and organic peroxides to water or corresponding alcohols, respectively, while oxidizing two GSH molecules to form GSSG [51]. This enzymatic detoxification system protects curtail biomolecules, including membrane lipids and functional proteins from oxidative damage. The GSH/GSSG redox cycle is maintained through NADPH-dependent regeneration of GSH from GSSG via glutathione reductase (GR), creating a sustainable antioxidant reservoir. This dynamic thiol-disulfide interchange system not only provides robust defense against oxidative stress but also modulates redox-sensitive signaling pathways through regulation of protein sulfhydryl groups. The interdependence between NADPH availability and GSH regeneration establishes a fundamental mechanism for preserving cellular redox poise under physiological and pathological conditions. Notably, redox regulation differs fundamentally between normal and malignant cells. Normal cells maintain low basal ROS levels with tightly controlled antioxidant responses, ensuring genomic integrity and signaling fidelity. In contrast, cancer cells operate under a state of chronic oxidative stress due to oncogene activation, metabolic rewiring, and hypoxic microenvironments. To survive under these conditions, malignant cells upregulate antioxidant systems, particularly NADPH and GSH production through 1C metabolism, creating a new redox equilibrium characterized by elevated ROS alongside enhanced buffering capacity. This altered redox state provides selective advantages for tumor progression, including increased mutation rates and adaptive signaling, while simultaneously rendering cancer cells more dependent on redox homeostasis mechanisms and thus more susceptible to therapeutic disruption. Effect of redox imbalance on biomacromolecules and cellular structures Structural perturbations in key amino acids disrupt 1C metabolism, compromises the production of antioxidant intermediates required to counteract ROS. The resultant cumulative ROS accumulation surpasses cellular detoxification capacity, precipitating a state of oxidative stress and redox imbalance [58]. ROS exhibits inherent chemical reactivity that drives indiscriminate modifications of biomolecules, inducing structural alterations, aberrant localization, disrupted intermolecular interactions and functional impairment. Given the pervasive involvement of redox imbalance across diverse metabolic pathways, a comprehensive enumeration of all affected biological macromolecules and cellular compartments exceeds the scope of this discussion. Consequently, we concentrate on oxidative damage mechanisms targeting nucleic acids integrity and mitochondrial structural alterations. Impact on genomic integrity and cancer-specific 1C alterations The maintenance of genomic integrity is tethered to a dynamic redox equilibrium governed by mitochondrial oxidative phosphorylation and 1C metabolic pathway. 1C metabolism serves as the critical determinant of cellular redox buffering capacity, primarily through the generation of NADPH, which is essential for the regeneration of reduced GSH and the functional integrity of the thioredoxin system. When ROS production exceeds the kinetic saturation of 1C-supported antioxidant systems, oxidative damage manifests as 8-oxodG and DSBs [59]. This process is not merely a bystander effect of metabolic stress but a causal driver of mutagenesis. We posit a self-reinforcing loop: 1C-deficiency-induced ROS causes initial DNA lesions, which impair the transcription of mitochondrial repair enzymes, leading to mitochondrial ETC dysfunction, further ROS leakage, and systemic genomic collapse [60]. The dysregulation of specific 1C metabolic intermediates significantly modulates this damage landscape across various malignancies. Crucially, the redox response of malignant cells undergo a fundamental redox resetting, characterized by chronically elevated ROS levels and a compensatory, albeit fragile, reliance on 1C-dependent antioxidant machinery (e.g., PHGDH or MTHFD2 overexpression). This adaptation creates a narrow therapeutic window: while cancer cells leverage these metabolic adjustments to support rapid proliferation, their proximity to the lethal threshold of oxidative stress makes them hypersensitive to interventions that disrupt NADPH/GSH synthesis. For instance, in phosphoglycerate dehydrogenase-amplified breast cancer and melanoma, the redirection of glycolytic flux toward serine synthesis is markedly upregulated [61]. This elevation in intracellular serine not only fuels nucleotide biosynthesis but also ensures a robust supply of glycine and cysteine for GSH production, allowing these cells to tolerate high ROS loads while maintaining genomic stability. Conversely, in MYC-driven lung adenocarcinoma, an overflow of formate, a key 1C intermediate is often observed; this formate surplus accelerates purine synthesis to support rapid proliferation, yet simultaneously alters the NADPH/NADP+ ratio, potentially sensitizing the genome to oxidative lesions if the antioxidant buffer is breached [62]. Furthermore, in hepatocellular carcinoma, depletion of SAM often leads to global DNA hypomethylation, which synergizes with ROS-mediated damage to promote chromosomal instability and the activation of oncogenic drivers [63]. These metabolic-redox-genomic axes illustrate that 1C metabolic defects do not merely permit DNA damage but actively shape the mutational signature of specific cancers by limiting the production of NADPH (essential for GSH recycling) or altering the availability of methyl donors. This interplay determines cell fate: depending on the magnitude of damage, cells may undergo ATM/ATR-mediated cell cycle arrest to allow for repair, or trigger p53-dependent apoptosis via Bax or p21 pathways to eliminate compromised cell [64]. However, surviving clones often leverage 1C metabolic flexibility to evolve resistance against persistent oxidative stress. This adaptability, which involves switching between mitochondrial and cytosolic 1C pathways, contributes to clonal evolution and malignancy. The convergence of metabolic dysfunction, redox imbalance and genomic instability forms a critical axis that not only underlies tissue-specific pathologies in response to abnormal 1C metabolic intermediates but also offers a compelling framework for understanding the shared etiology of cancer initiation. This triad creates a self-reinforcing cycle for tumor oxidative microenvironment, in which mitochondrial ROS damages nuclear DNA and impairs transcription of metabolic genes, then further exacerbates oxidative stress. Ultimately, deciphering this metabolic-redox-genomic network may unlock novel strategies to safeguard genomic health and mitigate mutation-related disease through targeted modulation of 1C metabolism or selective activation of damage clearance pathways. Redox imbalance disrupts mitochondrial function and metabolic homeostasis Under sustained environmental stress, prolonged overproduction of ROS causes cumulative damage to cellular structures and functions, potentially leading to somatic mutations and neoplastic transformation. Concurrently, the oxidative TME created by invasive tumors can itself be a source of oxidative stress, impairing major organelles such as mitochondria. In this context, 1C metabolism is co-opted to help neutralize the resulting oxidative burden. As central hubs of intracellular energy metabolism, mitochondria orchestrate nutrient catabolism for ATP production while simultaneously generating biosynthetic precursors. Thus, mitochondria must dynamically upregulate their antioxidant defense system to counteract redox imbalance. Critically, excessive ROS accumulation triggers a self-perpetuating cycle: mitochondrial dysfunction induces metabolic stress that paradoxically amplifies ROS generation through electron transport chain leakage, resulting in biomolecular damage and programmed cell death. Significantly, mitochondria-derived ROS exert dual oncogenic roles: directly inducing mtDNA mutations while simultaneously activating pro-tumorigenic signaling pathways through oxidative modification of nuclear transcription factors. Recent mechanistic studies reveal that serine catabolism through 1C metabolism serve as a redox rheostat within the mitochondrial matrix, maintaining NADPH/GSH pools with antioxidant responses [65]. This metabolic adaptation highlights mitochondrial essential role as both biosynthetic centers and gatekeepers against oxidative cascades that could otherwise initiate malignant transformation. Therefore, maintaining redox homeostasis through 1C metabolic adaptations enables mitochondria to effectively serve as central hubs for metabolic waste processing while safeguarding genomic integrity and cellular viability. Importantly, cell fate decisions are strongly influenced by ROS thresholds: moderate increases promote adaptive responses and proliferation, whereas excessive ROS accumulation beyond repair capacity triggers irreversible damage, leading to apoptosis or other forms of cell death. Remodeling immunosuppressive TME The TME constitutes a sophisticated biological niche characterized by dynamic interactions between malignant cells, resident immune populations, stromal constituents and extracellular matrix components [66]. A pathological hallmark of the TME is its profound immunosuppressive nature, which orchestrates tumor immune escape mechanisms and fosters neoplastic advancement through multiple signaling pathways. Notably, ROS demonstrate a concentration-dependent duality in their biological impacts: at physiological levels, they mediate crucial cellular signaling for immune activation, while excessive accumulation may promote oxidative stress and immunosuppression [67]. Given this context, the strategic modulation of 1C metabolism-derived intermediates to maintain redox homeostasis, coupled with the reprogramming of the immunosuppressive TME, has emerged as a critical therapeutic approach to enhance anti-tumor immunity and improve the effectiveness of cancer treatments (Fig. 5). ROS acts as promoter for immune activation ROS function as critical secondary messengers and promoter in immune activation, orchestrating both innate and adaptive immune responses through redox-sensitive signaling pathways. At physiological concentrations, ROS sustain T cell activation by amplifying T cell receptor (TCR) signaling cascades. Mechanistically, ROS-mediated TCR potentiation drives the nuclear translocation of key transcription factors, including nuclear factor of activated T cells (NFAT), activator protein-1 (AP-1) and nuclear factor kappa B (NF-κB), thereby coordinating T cell proliferation and effector functions [68]. Concurrently, ROS modulate macrophage plasticity by polarizing these cells toward a pro-inflammatory M1 phenotype, which mediates antitumor responses via enhanced phagocytic clearance, immunostimulatory cytokine secretion (e.g., TNF-α, IL-12) and tumor-associated antigen presentation. This dual regulatory role underscores the importance of maintaining ROS within a tightly controlled physiological range, as optimal redox balance ensures proper immunometabolic reprogramming, biosynthetic activity and functional coordination of immune effectors [69]. Excess redox leads to immunosuppression Maintaining redox equilibrium becomes particularly challenging when dysregulation occurs in 1C metabolism, a process critically dependent on key amino acids such as serine and glycine. Disruption of 1C metabolic pathways disrupts GSH homeostasis, culminating in excessive ROS accumulation. This redox imbalance disrupts antitumor immunity by crippling dendritic cell (DC) functionality, specifically impairing antigen cross-presentation to CD8+T cells, a process essential for priming adaptive antitumor responses [70]. Paradoxically, elevated ROS levels create a permissive niche for immunosuppressive cell populations, including M2-polarized macrophages, myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg cell) [71]. These immunosuppressive cells not only survive in high-ROS environments but also further amplify ROS production. This self-reinforcing cycle sustains immunosuppression through the secretion of immunosuppressive cytokines (e.g., IL-10, TGF-β) and upregulation of immune checkpoint molecules (e.g., PD-L1, CTLA-4). These mechanisms synergize with tumor-promoting matrix remodeling and angiogenesis, collectively driving malignant progression. Specifically, TGF-β not only inhibits T cell function but also induces PD-L1 expression on tumor cells, while simultaneously activating cancer-associated fibroblasts to deposit a pro-angiogenic extracellular matrix [72]. Such interactions establish a feedforward loop wherein tumor growth reinforces immunosuppression and vice versa. Severe ROS overload initiates a self-amplifying cytotoxic cascade, wherein oxidative damage to nuclear and mitochondrial DNA synergizes with metabolic collapse to propagate further ROS generation. This vicious cycle arises from mitochondrial dysfunction characterized by impaired ETC activity and increased mitochondrial membrane permeability. This permeability facilitates the release of mtDNA into the cytosol, where it activates the cGAS-STING pathway to initiate innate immune signaling thus causing nuclear DNA damage responses [73]. Concurrently, DSBs and base modifications activate poly(ADP-ribose) polymerase (PARP)-mediated repair pathways, depleting NAD+ reserves and exacerbating metabolic stress [74]. The resulting NAD+/ATP crisis destabilizes redox-sensitive signaling networks, as evidenced by oxidation-induced inactivation of AKT and AMPK-driven mTOR suppression, culminating in irreversible biomolecular damage through lipid peroxidation, protein carbonylation and RNA oxidation [75]. Non-malignant cells, particularly SOD2-low lymphocytes, undergo apoptosis or functional exhaustion under sustained oxidative pressure. In contrast, cancer cells adapt via dual stress-response mechanisms: HIF-1α-driven glycolytic reprogramming to bypass mitochondrial ROS and Nrf2-mediated upregulation of GPx4 to resist ferroptosis [76]. This dichotomy underscores the therapeutic imperative to precisely modulate redox homeostasis, suppressing tumor-promoting oxidative stress while preserving ROS-dependent immune activation through strategies such as antioxidant-boosted immunotherapy. Dysregulation of methylation donors drives epigenetic chaos SAM, the principal methyl donor in mammalian methylation processes, is generated through the methionine cycle and serves as a cornerstone for epigenetic and epitranscriptomic regulation [77]. Beyond its canonical role in mediating DNA and histone methylation, SAM has emerged as a critical modulator of genetic stability, bridging metabolic dynamics with mutagenic and adaptive mechanisms. Tumorigenesis is frequently characterized by elevated mutational stress, in terms of epigenetics, attributing to early microenvironmental stressors such as hypoxia, overnutrition, or redox imbalance that disrupt SAM homeostasis [78]. These stressors promote a state of epigenetic chaos driven by the dysregulation of methylation donors, as summarized in Table 2. This manifests via compromised DNA repair fidelity (e.g., through erroneous repair pathway choice or impaired damage sensing) and lead to chromosomal segregation errors, thereby accelerating mutation accumulation and fostering the evolution of cell populations toward increasingly aggressive phenotypes. Crucially, hypermethylation or the redistribution of methylation marks under these conditions disrupts the epigenetic landscape, thereby creating a permissive ‘breeding ground’ for the accumulation of mutations and oncogenic reprogramming. To unravel this nexus, we systematically dissect the tripartite roles of SAM-dependent methylation in DNA, histones and RNA, highlighting their convergent impacts on genomic integrity and tumor suppression. Elucidating these mechanisms not only advances our understanding of carcinogenesis but also unveils therapeutic opportunities to restore methylation equilibrium and intercept tumor progression. Table 2Epigenetic chaos driven by dysregulation of methylation donorsAffected epigenetic processDysregulation mechanismImpact on cancer developmentReferenceDNA MethylationFluctuations in SAM levels or SAM/SAH ratio impairing DNMT activity.TSG silencing via tumor suppressor gene promoter hypermethylation; proto-oncogene activation. [79, 108]Histone ModificationAltered 1C intermediates affecting HMT-mediated marks (e.g., H3K4, H3K9, H3K27).Aberrant transcriptional reprogramming and enhanced cell plasticity. [84, 109, 110]RNA MethylationSubstrate limitation for RNA methyltransferases (e.g., METTL3/14, NSUN family).Dysregulated mRNA stability and tRNA-dependent translational imbalance. [98, 106, 111]Heterochromatin and nuclear organizationImpaired H3K9me3-HP1 axis and disrupted NPCs assembly.Heterochromatin destabilization, activation of repetitive elements, and nuclear transport defects. [91, 94] Epigenetic chaos driven by dysregulation of methylation donors DNA methylation As established, the disruption of SAM homeostasis creates a landscape of aberrant DNA methylation. This dysregulation manifests primarily through two complementary mechanisms that collectively foster genomic instability and drive tumor progression: the transcriptional silencing of tumor suppressor (TSGs) and the direct induction of mutagenic events. Transcriptional silencing of tumor suppressors Under conditions of SAM imbalance, CpG-rich promoter islands of TSGs frequently become aberrantly hypermethylated. Molecular and genetic studies have demonstrated that this methylation leads to gene silencing through two primary mechanisms: direct steric hindrance that prevents transcription factors from binding to their regulatory elements, and the recruitment of methyl-CpG-binding domain proteins (MBDs) and associated repressor complexes to methylated regions. The assembly of these complexes promotes a condensed chromatin structure, further suppressing transcription [79]. However, aberrant DNA methylation, such as the hypermethylation of TSGs in cancer, can disrupt normal gene regulation (Fig. 6a and b). For example, hypermethylation of promoter regions in TSGs silences their expression, contributing to uncontrolled cell proliferation and tumor development [80]. Additionally, the methyl group of 5mC is located in the major groove of the DNA helix, where it can attract or repel DNA-binding proteins. For example, MBDs specifically recognize and bind to methylated CpG sites. These proteins recruit repressor complexes to methylated promoter regions, further contributing to transcriptional silencing [81]. DNA methylation affects genetic stability. a and b. DNA methylation associates with gene silencing. a Gene expression is normal when DNA is hypomethylated. b DNA hypermethylation associates with gene silencing. Transcription of most protein coding genes in mammals is initiated at promoters rich in CG sequences, where stretches of CpG-dense DNA are known as CpG islands. 5mC in these regions will directly interfere with the binding of transcription factor to DNA and further inhibit transcription. Red circles indicate methylation. c How DNA methylation causes mutations in genes. DNA bases can undergo spontaneous deamination. In this process adenine, guanine, cytosine and 5-mC rings lose their amino groups and form hypoxanthine, xanthine, uracil and thymine, respectively. Due to the body’s self-protection mechanism, these spontaneous deamination products can be excised from DNA by the enzymes such as uracil-DNA glycosylase, leading to error-free repair. However, thymine as one of the DNA bases will not be identified as an abnormal base by DNA repair enzymes. Thus, this substitution is retained in DNA replication to form a C to T point mutation, causing T-G mismatch In summary, to cope with environmental stressors, tumor cells harness DNA methylation in gene silencing manners by regulating transcription factor accessibility and recruiting repressive protein complexes to maintain survivable gene expression. DNA methylation as an endogenous mutagen Beyond its role in transcriptional silencing, DNA methylation serves as a significant source of endogenous mutations, directly linking epigenetic alterations to permanent genetic damage. This mutagenic property stems from the spontaneous deamination of 5-methylcytosine (5mC) to thymine [3]. While most these deamination products are recognized and excised by repair enzymes like uracil-DNA glycosylase, thymine resulting from 5mC deamination is not recognized as abnormal. As a result, this substitution is retained during DNA replication, leading to a C to T point mutation, causing T-G mismatch [82] (Fig. 6c). The functional consequences of these methylation-driven mutations are profound. They can introduce nonsense or missense mutations that inactivate critical tumor suppressors or activate oncogenes. These mismatches in the genome correspond directly to sites of nucleotide transitions, which are the most common type of genetic variation in humans. Thus, cytosine methylation is a major cause of point mutations and contributes significantly to genetic variation. To be specific, point mutations in the DNA ligase I gene can disrupt DNA replication, leading to DSBs [83]. Unrepaired DSBs drive genomic instability through chromosomal translocations and large-scale deletions, thereby accelerating the acquisition of oncogenic mutations. In summary, the dysregulation of DNA methylation serves as a critical mechanistic link between SAM homeostasis and tumor progression. By orchestrating the silencing of tumor suppressors and directly seeding the genome with point mutations and structural variations, SAM-dependent DNA methylation abnormalities create a permissive environment for the evolution of tumor cells toward more aggressive phenotypes. This process exemplifies how a perturbed metabolome and epigenome can directly destabilize the genome. Histone methylation Chromatin dynamics, governed by a diverse repertoire of post-translational modifications (PTMs) on histones, serve as a critical interface between metabolic state and gene expression [84]. As histone methyltransferases (HMTs) are strictly dependent on SAM, dysregulation 1C metabolism directly perturbs the histone methylation landscape. This epigenetic imbalance disrupts the transcriptional programs that govern cell identity and genetic stability, thereby creating a permissive environment for tumorigenesis (Fig. 7). The following sections dissect how aberrant histone methylation, through both the loss of repression and gain of activation, drives oncogenic transformation. Histone methylation associates with the alteration of genetic stability. The nuclear chromatin landscape is dynamically regulated between two principal states: euchromatin and heterochromatin, which are defined by distinct histone PTMs that modulate nucleosome packing density and transcriptional activity. In euchromatin, histones are loosely packed, allowing TFs and RNA polymerase (RNA Pol) to access DNA. This open chromatin state is enriched with transcription-activating histone marks, most notably H3K4me3, which accumulates at promoters of actively transcribed genes, peaking near the TSS. Collectively, such modifications are represented by H3K4me3 can coordinate splicing, maintain transcriptional stability, regulate cryptic transcription and sense-antisense transcriptions, as well as confer transcriptional memory, which are all associated with their promotion of transcription. In contrast, heterochromatin is characterized by tightly packed nucleosomes, physically blocking TF/Pol II recruitment to suppress gene expression. This condensed state is marked by repressive histone methylations, including H3K9me3 and H3K27me3. In addition, H3K9me3 heterochromatin is required for the formation of NPCs, which are channels that facilitate the continuous flow of molecules and macromolecules between the nucleus and cytoplasm. NPCs improve the transport efficiency of a kind of protein associated with gene regulation into the nucleus and ultimately help maintain the heterochromatin. This is why regions with more heterochromatins have a higher number of NPCs, whereas regions with more euchromatin have fewer Histone methylation regulate transcription Histone methylation is a key epigenetic mechanism that fine-tunes gene expression by modulating chromatin accessibility. Unlike DNA methylation, which predominantly represses transcription, the function outcome of histone methylation depends on the modified residue and its methylation state, leading to either transcriptional activation or repression [85]. This fidelity of histone methylation is critically dependent on SAM availability from 1C metabolism. Its dysregulation exerts a dual oncogenic impact: the aberrant acquisition of activating marks at oncogenes and the inappropriate imposition of repressive marks on TSGs. Oncogenic activation via aberrant histone methylation Under physiological conditions, specific histone methylation marks, such as trimethylation of histone H3 lysine 4 (H3K4me3), establish a permissive chromatin state at promoters of actively transcribed genes. Its abundance peaks near the transcription start site (TSS) and its distribution strongly correlates with transcription activity, making it a reliable marker of gene activation [86].Interestingly, aberrant deposition of H3K4me3 has been implicated in tumorigenesis by promoting the overexpression of proto-oncogenes. For example, in leukemia, fusion proteins of MLL (a histone methyltransferase) aberrantly deposit H3K4me3 at HOX gene clusters, driving their constitutive expression and sustaining malignant proliferation [87]. Similarly, in neuroblastoma, elevated H3K4me3 at the Myc promoter is correlated with its overexpression, a hallmark of aggressive tumors [88]. Thus, the pathological recruitment of activating marks to oncogenic promoters is a direct mechanism through which histone methylation dysregulation fuels cancer progression. Silencing of tumor suppressors via repressive histone methylation Conversely, repressive histone methylation marks are essential for maintaining the silent state of specific genomic regions, including heterochromatin and developmentally repressed genes. The dysregulation of these marks, particularly trimethylation of histone H3 lysine 27 (H3K27me3) and lysine 9 (H3K9me3), leads to the epigenetic silencing of TSGs. H3K9me is primarily linked to the formation of heterochromatin, a tightly packed chromatin state that silences gene expression. Moreover, H3K27me is catalyzed by polycomb repressive complex 2 (PRC2), recruits additional repressive complexes to lock genes in a transcriptionally inactive state [89]. Nevertheless, the impact of histone modifications on transcription is not absolute and can differ based on their genomic context. For example, methylation at H3K36 (H3K36me) is generally associated with active transcription when present within gene bodies, where it facilitates transcriptional elongation and splicing. Conversely, when H3K36me is located in promoter regions, it can repress transcription. Similarly, H3K9me, which is typically repressive in promoter regions, may have a distinct role in coding regions, where it could potentially contribute to transcriptional regulation in a context-dependent manner [85]. In some breast cancers, increased H3K9 methylation at the BRCA1 promoter silences its expression, impairing DNA repair and increasing genomic instability [90]. This inappropriate application of repressive marks effectively removes crucial barriers to cell proliferation and survival. In summary, histone methylation marks such as H3K9me and H3K27me are fundamental for establishing and maintaining repressive chromatin states, which are essential for proper gene regulation. However, their dysregulation can lead to epigenetic silencing of TSGs, driving cancer progression. The context-dependent nature of these modifications underscores the complexity of epigenetic regulation in both normal physiology and disease. The core mechanism underpinning heterochromatin-mediated genetic stability Chromatin exists in two primary states: transcriptionally active euchromatin and silent heterochromatin. This structural organization is dynamically regulated three interdependent mechanisms: PTMs of histones, chromatin remodeling complexes and DNA methylation [91]. Among these, histones PTMs play a pivotal role by modulating histone-DNA interactions, leading to the formation of tightly packed heterochromatin. These condensed regions restrict the access of transcription machinery to DNA, thereby enforcing stable, long-term gene silencing [92]. The integrity of heterochromatin is thus critical for suppressing spurious transcription and preventing genomic instability, and its disruption is an emerging hallmark of cancer. The defining epigenetic hallmark of heterochromatin is dimethylated or trimethylated histone H3 Lys9 (H3K9me2/3) [93]. These modifications serve as the molecular foundation for heterochromatin formation and maintenance. Mechanistically, H3K9me3 recruits heterochromatin protein 1 (HP1), an evolutionarily conserved effector that mediates gene silencing through three distinct actions. HP1 binds to H3K9me3 and subsequently recruits DNA methyltransferase (e.g., DIM-2) to strengthen heterochromatin silencing. Moreover, HP1 acts as a boundary element to prevent heterochromatin overextension and maintain the structural integrity of silent chromatin domains [94]. In tumorigenesis, the disruption of this H3K9me3-HP1-mediated pathway leads to global heterochromatin destabilization. This loss of structural integrity results in the aberrant expression of normally silenced repetitive elements and protooncogenes, while simultaneously compromising chromosomal segregation, thereby driving malignant transformation. Beyond its canonical role in gene silencing, H3K9me3-marked heterochromatin plays an unexpected role in nuclear organization by facilitating nucleopore complexes (NPCs) assembly [95]. As demonstrated by Sarkar et al., this process enhances nuclear import of chromatin regulators like SETDB1, creating a positive feedback loop that sustains heterochromatin stability [96]. Cancer cells often exploit this mechanism where dysregulated NPCs function due to altered H3K9me3 distribution can lead to the mislocalization of tumor-suppressor proteins, aberrantly transport oncogenic factors or ultimately promote tumor-specific phenotypes through nuclear transport defects. In conclusion, histone methylation, especially H3K9me3, is a core element of heterochromatin that determines its unique properties and functions. Through interactions with HP1, DNA methyltransferases and NPCs, histone methylation is proposed to play a critical role in the formation, maintenance and gene-silencing functions of heterochromatin, as well as in the regulation of related cellular processes. In oncology, deciphering these mechanisms provides a rational basis for developing epigenetic therapies targeting heterochromatin dysregulation in cancer cells. RNA methylation The central dogma of molecular biology delineates the unidirectional flow of genetic information from DNA to RNA to protein, with translation representing a critical regulatory node for cellular function [97]. Emerging evidence underscores RNA methylation as a pivotal PTM associated with the dynamic modulation of mRNA and tRNA stability, splicing and translational efficiency. These epigenetic-like modifications enable cells to rapidly adapt gene expression programs in response to environmental cues, while their dysregulation is increasingly implicated in pathological states, especially cancer, where metabolic reprogramming and RNA methylation are frequently co-opted to sustain aberrant gene expression programs. mRNA methylation regulated translation in physiology and cancer The dynamic modification of mRNA by N6-methyladenosine (m6A) represents a sophisticated mechanism for spatial control of protein synthesis, with profound implications for both normal cellular function and disease pathogenesis. As the most prevalent internal mRNA modification, m6A strategically positions itself across transcript regions to differentially regulate translation efficiency and fidelity [98]. Within coding sequences, these methylation marks subtly influence ribosomal decoding dynamics by modulating the interaction between aminoacyl-tRNAs and the ribosomal A site, creating a tunable mechanism that can either pause elongation for quality control or deliberately slow synthesis of specific proteins [99]. This fine-tuning capacity becomes particularly crucial when considering the contrasting effects observed in untranslated regions, whereas 5’ UTR-localized m6A marks bypass conventional cap-dependent initiation through direct engagement with eIF3, while their 3’ UTR counterparts enhance translational output via YTHDF1-mediated recruitment of ribosomal machinery [100, 101]. Beyond spatial organization, m6A deposition is fundamentally governed by cellular metabolic status, linking epitranscriptomic regulation to intracellular nutrient availability. The availability of SAM, the universal methyl donor, serves as a primary determinant of m6A writer activity. The core methyltransferase complex (METTL3/METTL14) directly utilizes SAM to catalyze methyl group transfer, rendering methylation patterns highly sensitive to one-carbon metabolic flux [54]. This process is further modulated by the intracellular SAM/SAH ratio, as SAH acts as a potent feedback inhibitor. Consequently, the m6A landscape is shaped by a bidirectional metabolic control system: while methylation capacity is tied to the methionine cycle via SAM availability, demethylation by erasers such as FTO and ALKBH5 is sensitive to oxygen, Fe2+ and α-ketoglutarate (α-KG) [102]. In cancer, widespread metabolic reprogramming exploits this sensitivity to reshape the transcriptome-wide methylation landscape. Elevated SAM availability is often associated with enhanced m6A deposition on transcripts that promote proliferation and survival, whereas disruptions in α-KG or redox balance can impair demethylase function [103]. The biological significance of this coupled system reaches into the realm of cancer biology, where its dysregulation manifests in multiple oncogenic processes. Hepatocellular carcinomas exemplify how corrupted m6A signaling can drive malignancy, as YTHDF2-mediated degradation of m6A-tagged SOCS2 transcripts removes a critical brake on JAK-STAT signaling [104]. Similar patterns of dysregulation are observed in metastatic breast cancer, where the stabilization of EMT-driving transcripts like SNAIL and TWIST confers increased invasive potential [105]. Collectively, the integration of metabolic cues with m6A-dependent translational control provides a conceptual framework for understanding how cancer cells exploit epitranscriptomic plasticity. As these mechanisms position m6A as a metabolically tunable layer of gene regulation, targeting components of the SAM-m6A axis may therefore represent a promising therapeutic strategy for malignancies characterized by coupled metabolic and RNA methylation dysregulation. tRNA methylation modulated translational fidelity and efficiency Beyond mRNA, cytosine-C5 methylation of tRNAs, catalyzed by DNMT2 and NSUN2 methyltransferases targeting non-anticodon loop regions, plays a critical role in protein synthesis. It stabilizes the tRNA tertiary structure, optimizes codon-anticodon interactions and regulates tRNA pool abundance, with deficiency resulting in global translation suppression [106]. Notably, RNA methylation participates in tumor microenvironment regulation. Altered m6A modifications in tumor-associated macrophages influence cytokine secretion, promoting immune evasion. Tumor cells can also remodel pre-metastatic niches by secreting extracellular vesicles containing specific methylation patterns. From a clinical perspective, RNA methylation machinery shows promise as both diagnostic biomarkers and therapeutic targets. Circulating m6A modification patterns are being developed as non-invasive diagnostic tools, while small-molecule inhibitors targeting METTL3 or FTO are under preclinical evaluation in various cancer models. These advances provide new directions for developing anticancer strategies based on RNA epigenetic regulation [107]. In summary, RNA methylation modifications, particularly m6A in mRNAs and C5 methylation in tRNAs, constitute a sophisticated regulatory network that fine-tunes protein synthesis through multiple complementary mechanisms. By influencing mRNA stability, ribosomal dynamics and tRNA functionality, these modifications provide cells with the ability to precisely modulate gene expression at the translational level. The growing understanding of these processes not only reveals their fundamental importance in normal cellular physiology but also highlights their potential as therapeutic targets for various diseases. Future research directions should focus on elucidating cell-type specific methylation patterns and their integration with other regulatory systems to provide a more comprehensive view of translational control in health and disease. Therapeutic strategies targeting aberrant 1C metabolism for cancer intervention The intricate interplay between folate cycle, the methionine cycle, and the trans-sulphuration pathway presents a broad spectrum of potential therapeutic targets (Fig. 8). The aberration of key amino acids and enzymes within this network, which may jeopardize genetic stability and drive cancer development, can be harnessed for therapeutic benefits. The overarching strategy is to selectively deprive cancer cells of the essential 1C units and redox donors required for their uncontrolled proliferation, disrupt their adaptive flexibility, while ideally sparing normal cells. This chapter delineates the therapeutic interventions aimed at each of the three interconnected cycles. Therapeutic strategies targeting aberrant 1C metabolism for cancer intervention. This figure illustrates the core mechanisms of aberrant one-carbon (1C) metabolism in cancer cells and the corresponding therapeutic strategies for targeted intervention Targeting folate cycle As the primary entry points for 1C units, folate cycle has been the most successfully targeted arm in oncology. The therapeutic goal is to inhibit nucleotide biosynthesis, thereby inducing replication stress and DNA damage, the very genomic instability that cancer cells often rely on but are vulnerable to when exacerbated. Classical antifolate drugs like methotrexate (MTX) are mainstays in the treatment of leukemias, lymphomas and other solid tumors, underscoring the critical dependence of tumor cells on sustained 1C unit supply for DNA synthesis [1]. As a DHFR-targeting agent, MTX depletes THF pools, halting thymidylate and purine synthesis. This leads to misincorporation of dUTP into DNA, resulting in DSBs and ultimately, cell death. However, classical antifolates are limited by extreme systemic toxicity and acquired drug resistance, which drive the development of novel antifolate strategies with improved efficacy and selectivity. Pemetrexed, a multi-targeted antifolate, addresses resistance by inhibiting multiple key enzymes in the 1C metabolic pathway, including TYMS, DHFR, thereby expanding its therapeutic spectrum and efficacy in cancers like non-small cell lung cancer and mesothelioma [112]. A more transformative advancement lies in the design of next-generation agents that selectively target enzymes over-expressed in cancer cells but minimally expressed in normal adult tissues, such as MTHFD2. By specifically blocking mitochondrial 1C unit supply through MTHFD2 inhibition, these agents exploit the metabolic addiction of cancer cells while sparing normal tissues, thus achieving a highly selective therapeutic window that classical antifolates lack [113]. This targeted approach not only mitigates the severe toxicity associated with traditional antifolates but also circumvents cross-resistance mechanisms, representing a paradigm shift in antifolate-based cancer therapy. Notably, emerging MTHFD2-targeting compounds and related antifolate strategies are currently being evaluated in early-phase clinical trials (summarized in Table 3), reflecting a shift toward precision targeting of cancer-specific metabolic dependencies. Table 3Selected clinical trials of drugs targeting 1C metabolism in cancerTargetDragPhaseNCTDNMT5-Fluoro-2’-deoxycytidine+TetrahydrouridineIINCT00978250DNMTGuadecitabineIINCT02684162DNMT14’-Thio-2’-DeoxycytidineINCT02423057DNMTDecitabineINCT00019825DNMTValproic AcidINCT02608736MGMTNivolumab+TemozolomideIIINCT02617589MGMTPatients+GlioblastomaIIINCT02667587TYMS+DHFRPemetrexedIINCT03086538TYMS5FUIINCT00682786TYMSZD1694INCT00001341MAT2AAG-270/S095033INCT03435250TYMS+DHFRPemetrexedIINCT00087113DHFRmethotrexateIIINCT00005585MAT2AIDE397INCT04794699MTHFD1/MTHFD2TH9619I/IINCT07151040 Selected clinical trials of drugs targeting 1C metabolism in cancer Nevertheless, inhibition of the folate cycle alone may be insufficient due to compensatory flux through parallel pathways, underscoring the need for rational combination therapies. Modulating the trans-sulphuration pathway Cancer cells often upregulate the trans-sulphuration pathway to divert Hcy away from methylation cycles toward GSH synthesis, enhancing their antioxidant defense to counteract oxidative stress and evade cell death. Therapeutic strategies aim to disrupt this defense, elevating ROS levels beyond a survivable threshold to induce apoptosis, necrosis, or ferroptosis. Normal cells, with lower baseline ROS levels and robust antioxidant buffering capacity, are less dependent on this pathway and can better tolerate such interventions, minimizing off-target toxicity. We propose that combining the trans-sulphuration pathway inhibitors with ROS-inducing therapies (e.g., cisplatin or radiotherapy) creates a powerful synthetic lethal interaction. By simultaneously increasing ROS production and disabling the primary antioxidant synthesis pathway, this combination overwhelms the adaptive capacity of cancer cells, driving them over the cytotoxic threshold [114]. Importantly, such combination strategies directly address metabolic flexibility by concurrently targeting ROS generation and detoxification systems, thereby limiting adaptive escape routes. Furthermore, dual restriction of methionine and its intermediates could result in more profound and sustained impairment of the antioxidant defense. Since methionine metabolism intersects with the trans-sulphuration pathway via Hcy recycling, co-targeting both pathways blocks compensatory mechanisms, thereby synergistically enhancing ROS-induced cytotoxicity. Disrupting the methionine cycle The methionine cycle serves as the central hub for cellular methylation reactions, including those modifying DNA and histones. Its dysregulation contributes to the epigenetic silencing of TSGs. Consequently, therapeutic strategies are being developed to target this cycle, primarily by depleting the universal methyl donor SAM, thereby reversing aberrant hypermethylation and restoring gene expression. A hallmark of many cancers is methionine addiction, a dependency on exogenous methionine despite a functionally intact intrinsic synthesis pathway. The duration of methionine restriction is a crucial: short-term deprivation or intermittent dietary methionine restriction can induce ferroptosis in these cells by upregulating the transcription of cation transport regulator homolog 1 (CHAC1) [115]. Beyond methionine, the dietary restriction of other intermediate metabolites from methionine cycle, such as Cys and GSH, represents promising strategies for cancer therapy. The efficacy of direct epigenetic drugs can be potentiated by simultaneously targeting the methionine cycle. Nucleoside analogs like decitabine and azacitidine incorporate into DNA and trap DNMTs, leading to their degradation. Pre-treatment or co-treatment with methionine restriction depletes the SAM pool, synergistically enhancing DNA hypomethylation. Consistently, DNMT inhibitors have been extensively evaluated in ClinicalTrials.gov-registered studies, and their combination with metabolic interventions is gaining increasing clinical interest (Table 3). This combination strategy promotes more robust and sustained reactivation of TSGs, potentially enabling the use of lower, less toxic doses of DNMT inhibitors. This approach has entered preclinical verification in leukemia and lymphoma models [116]. Therefore, targeting the methionine cycle is proposed to undermine the foundational machinery and sustains DNA hypermethylation to disrupt the adaptive flexibility of tumor cells. By depleting SAM, increasing the level of its inhibitory derivative SAH, or creating specific metabolic vulnerabilities, these interventions shift the epigenetic landscape away from a transcriptionally repressed state. The subsequent reactivation of critical TSGs is suggested to restore their anti-proliferative and pro-apoptotic functions, ultimately potentially inhibiting tumor growth and survival. Challenges and limitations in targeting 1C metabolism in cancer Despite the increasing recognition of 1C metabolism as a central regulator of tumor proliferation and genomic integrity, several formidable challenges impede its effective therapeutic exploitation. A primary obstacle lies in the profound metabolic plasticity of cancer cells, which enables a dynamic rewiring of 1C flux across interconnected subnetworks, including the folate cycle, methionine cycle, and trans-sulphuration pathway. This inherent flexibility allows tumor cells to circumvent the pharmacological blockade of a single enzymatic node by engaging alternative nutrient sources or compensatory biochemical routes. For instance, the inhibition of mitochondrial 1C enzymes such as SHMT2 or MTHFD2 may be effectively bypassed through the upregulation of cytosolic serine catabolism or the enhanced scavenging of exogenous metabolites like formate [117]. Consequently, such adaptive reprogramming markedly attenuates the clinical efficacy of single-pathway inhibition strategies, suggesting that only multi-node targeting can achieve sustained suppression. Furthermore, accumulating evidence underscores the context-dependent and, at times, ostensibly contradictory roles of 1C metabolism in tumorigenesis. While elevated 1C flux typically facilitates nucleotide biosynthesis and redox homeostasis, there are notable contexts where it may confer a metabolic liability rather than an advantage. These discrepancies are heavily dictated by the tumor lineage, the underlying genetic landscape (such as MYC amplification or p53 status), and the specific microenvironmental niche, all of which influence a tumor’s dependency on 1C-derived metabolites [88, 118]. This heterogeneity is further complicated by the narrow therapeutic window inherent to 1C-targeted agents; since this pathway is equally vital for the homeostasis of rapidly dividing healthy cells, such as hematopoietic progenitors and intestinal epithelium, potent inhibition often leads to significant systemic toxicity. Thus, identifying collateral lethality or tumor-specific vulnerabilities remains a prerequisite for minimizing off-target effects. Finally, substantial barriers persist in translating mechanistic insights derived from experimental models to the complexity of human disease. Much of our current understanding originates from in vitro cultures or murine models, which frequently fail to recapitulate the nutrient architecture of the human TME. Notably, standard culture media are often replete with supraphysiological concentrations of folate and serine, which may artificially inflate the apparent dependence of cancer cells on specific pathways while masking others. Moreover, critical interspecies differences exist between murine and human physiology, particularly regarding systemic nutrient flux and folate transport kinetics that may obscure potential therapeutic liabilities. These discrepancies likely contribute to the frequent disconnect between promising preclinical observations and the modest clinical performance of several 1C-targeted therapies. Collectively, these challenges underscore the imperative for more nuanced therapeutic paradigms, necessitating combinatorial strategies and the development of robust biomarkers for patient stratification. Conclusion Collectively, this review highlights that the precise regulation of 1C metabolism, tightly dependent on key amino acids, serves as a critical cellular safeguard for oncogenesis. Disruption of this network can initiate a self-perpetuating cascade of genomic instability, driven by epigenetic alteration and the accumulation of mutational burden. Notably, cancer cells actively exploit the oncogenic potential of 1C metabolism by exploiting its role in maintaining genetic stability, thereby converting it into a driver of tumor development. Through the integrated disturbance of nucleotide synthesis, methylation dynamics, and redox balance, aberrant 1C metabolism linking epigenetic reprogramming, genomic instability and oxidative stress, ultimately promoting malignant progression. In this context, targeting dysregulated 1C metabolic pathways represents a promising therapeutic avenue. This review synthesized current genetic and metabolic evidence across cancer types to support this perspective. The critical next step lies in translating this knowledge into clinical breakthroughs through the continued development of more effective and highly specific compounds. Acknowledgements A special thanks for the long-term subsidy mechanism from the Ministry of Finance and the Ministry of Education of PRC (People’s Republic of China) for BUCM (Beijing University of Chinese Medicine), and thanks for National Administration of Traditional Chinese Medicine High Level Key Discipline Construction Project of Traditional Chinese Medicine. Abbreviations Adenosine triphosphate Betaine-homocysteine methyltransferase Cystathionine β-synthase Cystathionine γ-lyase Dihydrofolate reductase Dimethylglycine Deoxythymidine monophosphate, thymidylate Deoxyuridine monophosphate Eukaryotic initiation factor 5 A Electron transport chain Folylpolyglutamate synthase General controlled non-repressed kinase 2 Glycine cleavage system Glutathione peroxidase Glutathione reductase Glutathione synthetase Glutathione disulfide Homocysteine Methionine adenyltransferase Methyl-CpG-binding domain proteins O-6-methylguanine DNA Methyltransferase Methylthioadenosine Mitochondrial tetrahydrofolate Methylen etetrahydrofolate reductase Mammalian target of rapamycin complex 1 Nucleopore complexes Phosphatidylcholine Phosphatidylethanolamine Polycomb repressive complex 2 Reactive oxygen species S-adenosylhomocysteine S-adenosylmethionine Sarcosine Serine hydroxymethyltransferase Threonine dehydrogenase Tetrahydrofolate Thymidylate synthase Tumor microenvironment One-carbon 5-methyl-THF 5,10-methylene-THF Authors’ contributions J.Y. and Y.L. designed the conception and drafted the manuscript. R.D. and X.B. prepared the figures.Q.L., Y.X., Y.Y. and W.Y. assisted in researching data for the manuscript. J.Y., Y.L., A.L. and C.L. supervised and revised the manuscript. All authors reviewed and approved the final manuscript. Funding This work was supported by the Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist University (Project ID: RC-IRMS/13-14/03). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Aiping Lyu, Email: aipinglu@hkbu.edu.hk. Cheng Lu, Email: lv_cheng0816@163.com. Yuanyan Liu, Email: yyliu_1980@163.com. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.